Latham & Watkins Advises on Viridian Therapeutics’ up to US$300 Million Credit Upsizing With Hercules Capital and Related US$300 Million Royalty Financing With DRI Healthcare

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, has announced it entered into a secured debt facility upsizing with Hercules Capital and royalty financing agreement with DRI Healthcare, and accelerated its timelines for the submission of the veligrotug BLA and the topline clinical data readouts of its VRDN-003 REVEAL trials in patients with thyroid eye disease (TED).

Latham & Watkins LLP represents Hercules in the transaction with a deal team led by partners Dan Van Fleet and Haim Zaltzman with counsel Emily Yu and associates Hyunji Lee and Scott Natsuhara. Advice was also provided on tax matters by partner Eric Cho; and on converts matters by partner Eric Rice.